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Abstract
E2F1 plays a key role in cell-cycle regulation in mammals, since its transcription factor activity controls genes re-
quired for DNA synthesis and apoptosis. E2F1 deregulation is a common feature among different tumor types and
can be a major cause of cell proliferation. Thus, blocking E2F1 expression by RNA interference represents a promis-
ing therapeutic approach. In this study, the introduction of specific short hairpin RNAs (shRNAs) reduced E2f1 ex-
pression by up to 77%, and impaired rat glioma cell proliferation by approximately 70%, as compared to control cells.
Furthermore, we investigated the expression of E2f1 target genes, Cyclin A and Cyclin E. Cyclin A was found to be
down-regulated, whereas Cyclin E had similar expression to control cells, indicating that gene(s) other than E2f1
control its transcription. Other E2f family members, E2f2 and E2f3, which have been classified in the same subgroup
of transcriptional activators, were also analyzed. Expression of both E2f2 and E2f3 was similar to control cells, show-
ing no cross-inactivation or up-regulation to compensate for the absence of E2f1. Nevertheless, their expression was
insufficient to maintain the initial proliferation potential. Taken together, our results suggest that shE2f1 is a promis-
ing therapy to control tumor cell proliferation.
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E2F comprises a family of transcription factor pro-
teins, with a pivotal role in controlling genes related to
cell-cycle progression (Helin et al., 1992; Kaelin Jr et al.,
1992; Shan et al., 1992). Eight E2F family members have
been identified so far, E2F1 to E2F8, whereas E2F1 to
E2F6 share the same structure: conserved DNA binding
and dimerization domains, and, except for E2F6, have do-
mains for transactivation and binding Pocket Proteins (PP):
p107, p130 and Rb (Retinoblastoma) (reviewed in Tsan-
toulis and Gorgoulis, 2005; DeGregori and Johnson, 2006).
In general terms, the E2F family can be functionally classi-
fied in two subgroups, namely transcriptional activators
(E2F1 to E2F3a) and repressors (E2F3b to E2F8). The E2F
dimerization domain binds to members of the DP protein
family, and the resulting complexes regulate overlapping
gene collections (DeGregori and Johnson, 2006).
Despite Rb having been found to be associated with
many members of the family, E2F1 is its main target (Wells
et al., 2003; Frolov and Dyson, 2004). Rb phosphorylation
by Cyclin D/CDK4 and Cyclin E/CDK2, in late G1 phase,
releases E2F transcription factors, thereby promoting ex-
pression of genes related to DNA synthesis and cell-cycle
progression, resulting in cell proliferation (Polyak et al.,
1994; DeGregori et al., 1995). The dissociation of E2F
from pRb protein seems to be the main determinant in regu-
lating cell proliferation, by permitting transactivation of
genes such as cyclin A, cyclin E, c-myb, cdc2, PCNA and
thymidine kinase, and committing cells to S phase (DeGre-
gori, 2002).
The best characterized gene of the E2F family is
E2F1, which plays a paradoxical role by acting in two op-
posing pathways: induction of cell cycle progression and
apoptosis (Pierce et al., 1999). E2F1, in response to DNA
damage, can induce apoptosis by regulating related genes
in a p53-dependent and p53-independent manner (Bates et
al., 1998; Irwin et al., 2000; Lissy et al., 2000; Moroni et
al., 2001).
Dysfunction of the intricate cell-cycle regulation
pathways described above can exacerbate cell growth and,
eventually, lead to cancer-cell development. In fact, dereg-
ulation of E2F1 gene expression is a common event in the
majority of tumors, where it appears over-expressed rather
than mutated (Sherr, 1996; Dyson, 1998). E2F1 over-
expression is due to a positive feedback loop created be-
tween this protein and its own promoter and due to high
pRb phosphorylation levels or lack of functional pRb, both
resulting in the liberation of E2F1. The main reasons for
this hyperphosphorylation are high CDK4/6 and CDK2 ac-
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tivity, the absence of Cdk inhibitors (CDIs) and over-
expression of Cyclins (reviewed in Halaban, 2005).
Since Rb is the most important PP and is preferen-
tially associated with E2F1, inactivation of E2F1 seems to
be a promising therapy for impairing the proliferation of
different tumor types and in other diseases where cell pro-
liferation is a secondary effect, like vascular smooth muscle
cell hyperplasia. Furthermore, the function of E2F1 in con-
trolling the expression of other genes, such as Cyclin A and
Cyclin E, and its overlapping function with other E2F mem-
bers, namely E2F2 and E2F3, are controversial (Ohtani et
al.,1995; DeGregori et al, 1995; Takahashi et al., 2000;
Goto et al., 2006; Kong et al., 2007), thereby necessitating
further characterization.
In this study, our aim was to develop short interfering
RNAs for the impairment of cancer cell proliferation in vi-
tro. E2f1 was elected as the target, as its expression plays a
key role in cell-cycle progression, besides being up-regu-
lated in most types of tumor (Sherr, 1996; Dyson, 1998).
We employed the rat glioma cell line, C6, as an in vitro can-
cer model, and showed that the shE2f1 (short hairpin RNA
against E2f1 mRNA) is a potent tool for impeding cell pro-
liferation, since it diminished C6 proliferation 3.5 to 4-fold.
Furthermore, we also examined the effects of shE2f1 on the
expression of two other members of the E2f family, E2f2
and E2f3, to explore whether any cross-inhibition or com-
pensatory mechanisms were occurring. The expression of
Cyclin A and Cyclin E was also assessed to investigate E2f1
transcriptional regulation of these genes.
Three different shRNAs were designed for interfer-
ence with the rat E2f1 transcript at distinct regions
(shE2f1A, B and C), and were inserted into the pBS/hU6-1
plasmid vector (generously provided by Dr. David Balti-
more - California Institute of Technology, CA- USA – Qin
et al., 2003) yielding pBSE2f1A, B and C. As control, an
additional vector (pBSshGFP) containing a shRNA against
eGFP RNA (enhanced Green Fluorescent Protein) was also
generated by using a previously validated target sequence
described by Tiscornia et al. (2003) and Mousses et al.
(2003). None of the target sequence shows any significant
homology to other rat gene sequences. Therefore, synthetic
oligonucleotides (Invitrogen) were designed (listed in Ta-
ble 1) and cloned as described by Qin et al. (2003). The
generated constructs were confirmed by sequencing, using
25 ng of the respective primers T3 and T7 (Stratagene) and
the ABI Prism – Big Dye Terminator Cycle Sequencing
Ready Reaction Kit, with an ABI377 sequencer, according
to manufacturer’s instructions (Perkin-Elmer).
The rat glioma cell line, C6 (ATCC CCL-107), was
cultured in Dulbecco’s Modified Eagle’s minimum essen-
tial medium (DMEM high glucose), supplemented with
10% fetal bovine serum (FBS) and penicillin/streptomycin
(Invitrogen) at 37 °C/5% CO2. C6 cells were plated at 80%
confluence and co-transfected, using lipofectamine (Invi-
trogen) with 3 g of a plasmid DNA mixture containing
pBABEpuro and pBSshE2f1 -A, -B, -C or pBSshGFP
(1:10, respectively), whereas pBS/hU6-1 derived plasmids
were previously digested by XmnI, according to manufac-
turer’s protocol (BioLabs). After co-transfection, cells
were selected using 400 ng/mL of puromycin. As the first
step towards identifying the most effective pBSshE2f1,
several clones, denominated C6shE2f1-A, -B, -C and
C6shGFP, were obtained from each co-transfection and
maintained in selective medium. Their genomic DNA was
extracted with lysis buffer (100 mM Tris-HCl, pH 8.5;
5 mM EDTA; 0.2% SDS; 200 mM NaCl; 100 g/mL of
proteinase K), to verify the presence of pBS/hU6-1 derived
plasmids by PCR using 25 ng of each of the primers T3 and
T7 (Stratagene), according to manufacturer’s instructions.
pBS/hU6-1 was used as negative PCR control. Positive
clones were selected and used in subsequent experiments.
In order to assess the proliferation-altering potential
of each shRNA vector, the parental C6 cell line (triplicate)
and different clones of C6shE2f1-A (3 clones), -B (5 clo-
nes), -C (3 clones) and C6shGFP (4 clones) were analyzed
by a growth curve assay. At day zero, 5 x 104 cells from
each of the different clones (C6shE2f1-A; -B; -C; -shGFP),
as well as the parental C6 cell line, were each seeded into 10
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Table 1 - Oligonucleotide sequences to construct pBS/hU6-1 encoding different shRNAs.
shRNAs name Oligonucleotide sequencea
shE2f1-A sense (273)b 5’ACCgACCACCAAACgCTTCTTgTTCAAgAgACAAgAAgCgTTTggTggTCTTTTTC 3’
shE2f1-A antisense 5’TCgAgAAAAAgACCACCAAACgCTTCTTgTCTCTTgAACAAgAAgCgTTTggTggT 3’
shE2f1-B sense (426) 5’ACCgAATCATATCCAgTggCTATTCAAgAgATAgCCACTggATATgATTCTTTTTC 3’
shE2f1-B antisense 5’TCgAgAAAAAgAATCATATCCAgTggCTATCTCTTgAATAgCCACTggATATgATT 3’
shE2f1-C sense (246) 5’ACCgTCACgCTATgAgACCTCATTCAAgAgATgAggTCTCATAgCgTgACTTTTTC 3’
shE2F1-C antisense 5’TCgAgAAAAAgTCACgCTATgAgACCTCATCTCTTgAATgAggTCTCATAgCgTgA 3’
shGFP sense 5’ACCgCAAgCTgACCCTgAAgTTCTTCAAgAgAgAACTTCAgggTCAgCTTgCTTTTTC 3’
shGFP antisense 5’TCgAgAAAAAgCAAgCTgACCCTgAAgTTCTCTCTTgAAgAACTTCAgggTCAgCTTg 3’
a: underlined, 9-nucleotide spacer sequence.
b: in parenthesis, starting nucleotide of shRNA target, based on GenBank accession number XM 230765.
dishes, 35 mm in diameter, with DMEM supplemented
with 5% FBS. At indicated times, each clone and the paren-
tal cells were sampled in duplicate. The final results shown
in Figure 1 represent the average among clones of each
type. The culture medium was replaced every two days.
The data presented indicate that construct pBSshE2f1-B
significantly impaired the proliferation of C6 cells when
compared to controls. A comparative analysis at day 9
showed that C6shE2f1 B cell proliferation was 3.5 to 4
times lower than that observed in the controls, these cells
remaining with only 30% of the proliferative capacity ob-
served in C6shGFP cells.
Total RNA was extracted from C6 (parental cell line),
and clones C6shGFP-6 (control cells), C6shE2f1-A22,
C6shE2f-C3 and 2 different clones from C6shE2f1-B (B7
and B11), by using Trizol (Invitrogen) according to manu-
facturer’s protocol (see Figure 1). This was carried out on
the 7th day of the growth curve, so as to ensure exponential
growth and synchronized phases between the different
cell-lines. This procedure was employed to minimize dif-
ferences in E2f1 expression due to the manner in which the
cells were handled, and because E2f1 expression cycles
during cell division. After RNA integrity was confirmed,
each sample was treated with DNase I (Invitrogen) to avoid
DNA contaminants, and purified by phenol/chloroform ex-
traction before reverse transcription. An aliquot of 2 g of
RNA was used for first strand cDNA synthesis by priming
with an oligo dT primer and using SuperScript II Reverse
Transcriptase (Invitrogen) according to manufacturer’s in-
structions. To control for DNA contamination of the cDNA
samples, cDNA synthesis was performed in either the pres-
ence or the absence of reverse transcriptase. Samples were
used as template for real time PCR amplification, where
each cDNA was sampled in triplicate to detect E2f1, E2f2,
E2f3, Cyclin A and Cyclin E gene expression. Real time
PCR was performed in an ABI Prism 7700 Sequence De-
tection System (Applied Biosystems), according to manu-
facturer’s guidelines. Expression of -actin was assessed as
an internal control, and used to calculate relative quantifi-
cation as described by Pfaffl (2001). Each pair of primers
was designed using Primer3 software, and their sequences
are as follows: E2f1 F - 5’ TGTGCCCTGAGGAAAGTG
3’; E2f1 R - 5’ AAGGTTGGGGATGTGGAG 3’; E2f2 F -
5’ AGTTCCTGTCCCCAATCCT 3’; E2f2 R - 5’
GAGCCTGTCAATCTGTCTGTG 3’; E2f3 F - 5’
GCCCATTGAGGTTTACTTGTG 3’; E2f3 R - 5’
CCAGAGGAGAGAGGTTTGCT 3’ (designed using as a
template GenBank database E2f3 LOC291105 - E2f3 pre-
dicted from genome rat); Cyclin A F - 5’ TTTGCCA
TCGCTTATTGCT 3’; Cyclin A R - 5’ TGTGGTGCTT
TGAGGTAGGT 3’; Cyclin E F - 5’ CTCGCTGCTTCT
GCTTTGT 3’; Cyclin E R - 5’ TGTGGGTCTGGATGTT
GTG 3’; -actin F 5’- ACCAACTgggACgATATggAgA
AgA - 3’; and -actin R 5’- TACgACCAgAggCATACA
gggACAA - 3’ (Invitrogen).
Detection of E2f1 expression was performed in these
samples by real time PCR to investigate shE2f1 efficiency.
A comparative analysis of E2f1 expression between one
clone of each construct C6shE2f1 (-A22; -B7; -3C), C6 pa-
rental line and control clone C6shGFP-6 is presented in
Figure 1b. The figure shows that E2f1 is more efficiently
knocked down in C6shE2f1-B cells. These results are con-
sistent with phenotypic observations.
Based on these results, two clones, C6shE2f1-B7 and
-B11, were chosen to test E2f1 expression by real time
PCR. A comparative analysis of E2f1 expression between
two C6shE2f1-B clones (B7 and B11) and control clone
C6shGFP6 is presented in Figure 2a. The data show that
E2f1 was knocked down by as much as 77% in C6shE2f1-B
clones. The data are in accordance with inactivation by
RNA interference (RNAi) of other genes, as described in
the literature (Shi, 2003). Therefore, knockdown E2f1 ex-
pression significantly impairs cell proliferation. These re-
sults are in disagreement with those of Humbert et al.
(2000) and Wu et al. (2001), who suggest that E2f1 does
not play a key role in cell proliferation, since cell division in
the E2F1 knockout mouse is maintained. However, the
cells used in their experiments were not malignant, as is C6,
and so there was no exacerbated proliferation or the accu-
mulation of genetic alteration.
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Figure 1 - Phenotypic assay to assess activity of shE2f1. (a) In this growth
curve, the data represent the mean cell number observed from parental C6
cells (triplicate), C6shGFP (4 clones), C6shE2f1-A (3 clones),
C6shE2f1-B (5 clones) and C6shE2f1-C (3 clones) at the indicated time
points. (b) Quantification of E2f1 transcript levels by real time PCR. E2f1
expression profile in cells C6, C6shGFP clone 6 (C6shGFP-6), and one
clone from each of the different constructs C6shE2f1(-A22; -B7; -C3). Re-
sults were normalized by comparison to -actin expression levels. cDNAs
were synthesized from RNA obtained from synchronized cell cultures.
The PCR assay is representative of the several assays performed.
We showed that knockdown of E2F1 by RNAi is a
promising approach to impair unwanted cell proliferation,
but we have not yet explored the impact of reduced E2F1 on
apoptosis. In E2f1 knockout mice, thymocytes revealed
low levels of apoptosis and the animals had a high fre-
quency of spontaneous tumor formation from different tis-
sues (Field et al., 1996; Yamasaki et al., 1996). If designing
a treatment strategy based on the induction of apoptosis,
then shE2f1 may not be an appropriate option. Neverthe-
less, E2F1 is not the only factor involved in controlling the
apoptosis pathway, since tumors can undergo apoptosis in
the absence of its expression (Baudino et al., 2003). There-
fore, the choice of treatment could depend on the back-
ground of each tumor.
The E2F family includes 8 genes, most of which are
involved in cell-cycle regulation. Only E2F1 to E2F3a are
known to exert overlapping functions on inducing cell pro-
liferation (Blais and Dynlacht, 2004). To test the influence
that the lack of E2f1 may exert over the E2f2, E2f3, genes,
their expression levels were also assessed (Figure 2a).
Their expression was not affected in C6shE2f1-B clones,
when compared to control cells. These results suggest that:
i) shE2f1-B does not disrupt E2f2 and E2f3 expression,
thereby proving its specificity; ii) E2f1 is not responsible
for controlling E2f2 and E3f3 expression; iii) E2f2 and
E2f3 do not compensate for the absence of E2f1 in cell pro-
liferation, thus demonstrating that E2f1 was the major pro-
mitotic effector under the present experimental conditions.
Our data are in agreement with a recent study on HeLa
cells, where the authors inhibited E2F1 by siRNA, and ob-
served no effect on E2F2 expression (Goto et al., 2006),
and are also consistent with a study on double-knockout
cells, where the authors found that E2F3 protein levels were
unaffected by loss of E2F1/E2F2 (Li et al., 2003). How-
ever, our findings are in contrast to those of Kong et al.
(2007), as these authors conclude that the long-term loss of
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Figure 2 - (a) E2f1, E2f2 and E2f3 expression profile in C6shGFP cells, clone 6, and C6shE2f1-B clones 7 and 11. (b) Expression profiles of E2f1 target
genes, Cyclin A and Cyclin E, to evaluate their response to altered E2f1 levels. Expression of the indicated genes was determined as described legend of
Figure 2. PCR reactions were performed three times.
E2F activity leads to compensation by other family mem-
bers. Nevertheless, our data were obtained from established
clones and no compensatory effects were observed. A pos-
sible explanation for these different observations may be
due to the different cell types that were utilized. Knock-
down of E2F1 in cells with normal E2F1 expression may
release a compensatory response in E2F2 and E2F3 expres-
sion, whereas in cancer cells, which usually over-express
E2F1, knock down of this gene may not have a compensa-
tory effect by other members of the family, thus being suffi-
cient to impair proliferation.
Genes controlled by E2F1 have been described in a
few studies where E2F1 was over-expressed. Cyclin A and
Cyclin E were found to be over-expressed in response to
E2F1, thereby demonstrating a direct correlationship be-
tween E2F1 and its targets (Ohtani et al., 1995; Inoshita et
al., 1999, Takahashi et al., 2000). The expression of these
two genes was also assessed in a double-knockout model
for E2f1/E2f2, where Cyclin A was down-regulated and
Cyclin E was not significantly influenced (Li et al., 2003).
In contrast to these findings, Goto et al. (2006) revealed a
different view by demonstrating that the lack of E2F1 does
not negatively influence Cyclin A and Cyclin E. Because of
the controversial function of E2F1 in controlling expres-
sion of genes involved in cell-cycle progression, we also
analyzed Cyclin A and Cyclin E gene expression in
C6shE2f1-B cells by real time PCR (Figure 2b). In accor-
dance to E2F1 overexpression studies, Cyclin A was
down-regulated in our cells when compared to controls,
thus accompanying E2f1 knockdown. However, this was
not the case for Cyclin E, where expression was not signifi-
cantly changed, when compared to control cells. This sug-
gests that E2f1 does not control Cyclin E expression in C6
cells. However, continued expression of Cyclin E does not
compromise the use of shE2F1-B in diminishing cell prolif-
eration.
In conclusion, specific inactivation of E2f1 was suffi-
cient to impair cell proliferation by 70%, and RNAi meth-
odology seems to be an effective tool for targeting
unwanted cell proliferation. Further investigation of these
shRNAs in other cell-lines may provide additional infor-
mation about this tool. Nevertheless, we have shown that
shE2F1-B was capable of reducing the expression of E2f1,
as well as impeding cell proliferation. With further devel-
opment, shRNA against E2f1 may prove to be an interest-
ing strategy in the treatment of proliferative diseases, such
as cancer and other physiopathological conditions, includ-
ing neointimal hyperplasia associated to cardiovascular de-
rangements.
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